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Bovine babesiosis, caused by Babesia bovis, is a global tick borne hemoprotozoan parasite disease charac-
terized by fever, anemia, weight losses and ultimately death. Several babesicidal drugs that have been in
use in cattle for years have proven to be only partially effective and the development of alternative che-
motherapeutics that are highly speciﬁc and have low toxicity against babesiosis is needed. Triﬂuralin
derivatives speciﬁcally bind alpha-tubulin in plants and protozoa parasites causing growth inhibition.
A set of 12 triﬂuralin analogues (TFLA) has previously been shown to be inhibitory for the growth of Leish-
mania species. The conservation of several key amino acids involved in the triﬂuralin binding site of
alpha-tubulin among Leishmania sp. and B. bovis provides rationale for testing these compounds also
as babesiacides. The previously tested Leishmania inhibitory, TFLA 1–12 minus TFLA 5, in addition to three
novel TFLA (termed TFLA 13–15), were tested against in vitro cultured B. bovis parasites. While all of the
TFLA tested in the study showed inhibition of B. bovis growth in vitro TFLA 7, TFLA 10 and TFLA 13, were
the most effective inhibitors with estimated IC50 (lM) at 72 h of 8.5 ± 0.3; 9.2 ± 0.2; 8.9 ± 0.7, respectively
for the biologically attenuated cloned B. bovis Mo7 strain, and 13.6 ± 1.5; 18.7 ± 1.6; 10.6 ± 1.9, respec-
tively for the virulent B. bovis T3Bo strain. The differences found between the two strains were not statis-
tically signiﬁcant. Importantly, these drugs displayed low levels of toxicity for the host erythrocytes and
bovine renal arterial endothelial cells at the doses tested. The demonstrated ability of triﬂuralin ana-
logues to inhibit in vitro growth of B. bovis parasites combined with their low toxicity for host cells sug-
gests that these compounds may be further developed as novel alternatives for the treatment of bovine
babesiosis.
 2013 Australian Society for Parasitology. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Bovine babesiosis is caused by intraerythrocytic protozoan par-
asites of the genus Babesia. Babesia parasites are transmitted by
Ixodid ticks mainly in tropical and sub-tropical areas worldwide
(Boustani and Gelfand, 1996; Homer et al., 2000; AbouLaila et al.,
2010). Clinical symptoms can include fever, hemolytic anemia,
hemoglobinuria, and severe clinical cases may be followed by sud-
den death (AbouLaila et al., 2010). However, it is widely recognized
that Babesia bovis causes higher morbidity and mortality than
Babesia bigemina (Suarez and Noh, 2011). The only preventivetreatment available against bovine babesiosis is based in live-
attenuated vaccines that are commonly used in Australia, Argen-
tina, South Africa and Israel (Vial and Gorenﬂot, 2006), but these
vaccines are not licensed for use in the US or in many other coun-
tries. Therefore, vaccine use is limited or not widely available in
several countries; consequently treatment of cattle with babesia-
cides plays a central role in the management of this disease.
Babesiacides currently available for treatment of cattle, horses,
dogs and other animals include imidocarb dipropionate (Imizol,
Schering-Plough Animal Health) and diminazene aceturate (Bere-
nil, Intervet, India Pvt. Ltd.). In addition, quinine, clindamycin
and atovaquone (Mepron, Glaxo Welcome) are available for use
in humans (Vial and Gorenﬂot, 2006). Most of these babesicidal
drugs have proven to be ineffective owing to problems related to
their toxicity, residual effects, and the development of resistant
parasites (Bork et al., 2005; Vial and Gorenﬂot, 2006; Suarez and
Noh, 2011). Consequently, the identiﬁcation of new parasite-spe-
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critical.
Cell microtubules are rapidly assembled and disassembled to
create structures that are essential for the development of eukary-
otic cells. The current availability of microtubule inhibitor drugs
and the occurrence of extensive sequence differences among the
proteins involved in these processes among protozoa and the cells
of their hosts, suggests that they could be potential drug targets.
Compounds that disturb intracellular processes involving microtu-
bules are often used to treat medical conditions, including cancer,
gout, and helminth infections (Jordan et al., 1998). Certain micro-
tubule inhibitors, including vinblastine and taxol, display potent
activity against parasites by disrupting the microtubular structures
of the host erythrocyte, which make them potentially toxic for
mammalian cells. In contrast, antimitotic herbicides, namely dini-
troanilines (e.g. triﬂuralin, ethaﬂuralin and oryzalin) that bind
tubulin heterodimers and disrupt microtubule in plant cells (Chan
and Fong, 1990; Simoncelli et al., 2003; Hashim et al., 2012), do not
affect the function of mammalian and fungal tubulins (Chan and
Fong, 1990). However, these compounds do inhibit the growth of
numerous protozoan parasites such as Leishmania species,
Toxoplasma gondii, Trypanosoma cruzi and the Babesia, related
major human malarial parasite Plasmodium falciparum, in culture
(Traub-Cseko et al., 2001; Werbovetz, 2002; Fennell et al., 2006;
Naughton et al., 2008). Signiﬁcantly, triﬂuralin analogues are
known not to be lytic or toxic for bovine erythrocytes. Studies
performed by Mitra and Sept, 2006 demonstrated that bovine
alpha- (a-) tubulin lacks the known consensus binding site for
dinitroanilines, and thus displayed only nonspeciﬁc and low-
afﬁnity interaction with these compounds (Chan and Fong,
1990). Taking together, these observations suggest that dinitroani-
lines such as triﬂuralin, while having a great potential for
inhibiting protozoan development, might have limited toxicity
for the mammal hosts, and thus they could be considered as strong
candidates for the development of new alternative and non-host
toxic babesiacides.
Triﬂuralin is effective against the cutaneous form of leishmani-
asis when delivered as an ointment (Chan et al., 1993; Esteves
et al., 2010). However, its use for controlling other forms of leish-
maniasis, namely by parenteral administration, has been limited
by its low water solubility and easy sublimation (Mamy et al.,
2005). To address these undesirable properties that are character-
istic of the dinitroanilines, twelve new triﬂuralin analogues (TFLA)
(termed TFLA 1–12) incorporating chemical modiﬁcations in the
amine group have been developed, resulting in novel and more
effective compounds with increased inhibitory activity on the
growth of Leishmania donovani and Leishmania infantum in vitro
(Esteves et al., 2010).
In this study, we ﬁrst determine that some a-tubulin amino acid
residues that are known to participate in the binding site for dini-
troanilines in other protozoa parasites are also conserved among B.
bovis. Based on this observation, we assessed the efﬁciency of the
TFLA 1–12 and the newly synthetized TFLA 13–15 to inhibit the
growth of B. bovis in in vitro cultures. The data collected in this
study demonstrates that all previously tested Leishmania inhibitory
TFLA as well as the newly synthetized TFLA are able to inhibit the
growth of B. bovis in vitro, apparently without seriously compro-
mising the host erythrocyte cells.2. Material and methods
2.1. Multiple alignments of a-tubulin sequences
The a-tubulin amino acid sequences from several parasites
were aligned using the program ClustalW available at http://www.genome.jp/tools/clustalw/. The GenBank accession no.
are: Leishmania major (CAJ02502.1, locus tag: LMJF_13_0380);
Trypanosoma brucei gambiense (CBH08955.1, locus tag:
TbgDal_I1360); P. falciparum (CAA34101.1); T. gondii
(AAA30145.1); B. bovis (EDO06790.1, locus tag: BBOV_IV004290);
Theileria annulata (XP_954407.1, locus tag: TA21240) and Homo
sapiens (NP_116093.1).
2.2. General procedure for TFLA synthesis
All reagents and solvents were of the purest grade available, and
generally were used without further treatment. The starting mate-
rials, chloralin, imidazole, benzimidazole and sulfanilamide were
purchased from Sigma–Aldrich, Europe.
Synthesis of TFLA was performed as previously described (Este-
ves et al., 2010). Brieﬂy, the triethylamine (1.1 mmol) and the cor-
responding amine (1.1 mmol) were added simultaneously into a
solution of chloralin (1 mmol) in ethanol (5 ml) under nitrogen
atmosphere. The mixture was reﬂuxed until complete consump-
tion of amine (0.5–1 h), as monitored by thin layer chromatogra-
phy (TLC), cooled to room temperature, poured into ice-water
and extracted with ethyl acetate. The organic extracts were dried
over magnesium sulfate, ﬁltered and concentrated in vacuum to
obtain a solid residue. The residues were puriﬁed by silica column
chromatography and/or recrystallization to afford the products as
crystalline solids.
Melting points were determined in a Reichert Thermovar
apparatus and are uncorrected. FTIR spectra were recorded on a
Perkin-Elmer Spectrum BX v5.3.1 spectrometer. UV/VIS spectra
were recorded on a Hitachi U-2800A spectrophotometer. Fourier
transform (FT) NMR spectra were run on a BRUKER, AVANCE
400 MHz Ultra Shield spectrometer at Faculty of Sciences of Lisbon
University. The chemical shifts are reported in d (ppm, TMS) and
coupling constants in Hz. Electronic Impact (EI) mass spectra
(MS) and Electron Spray Ionization (ESI) mass spectra were per-
formed on a Brucker Daltonics Apex-Qe instrument at 300.0 V at
CACTI of Vigo University. Microanalyses were performed on a
Fisons EA-1108 microanalyzer at CACTI of Vigo University. TLC
was performed on silica gel 60 F254 plates with 0.2 mm layer
thickness from Macherey-Naguel, and the compounds visualized
by illumination under UV light at 254 nm. Column chromatogra-
phy (CC) was carried out with Macherey Naguel Si gel 60
(230–400 mesh).
2.2.1. 1-(2,6-Dinitro-4-triﬂuoromethyl-phenyl)-1H-imidazole (TFLA
13)
The general method for synthesis was used with chloralin
(0.273 g, 1 mmol), triethylamine (0.15 ml, 1.1 mmol) and 1H-imid-
azole (0.068 g, 1.1 mmol) to obtain the product as light yellow
crystals (dichloromethane/hexane, g = 62%). mp 168–169 C. FTIR
(KBr): m 3430, 3094, 1553, 1318 cm1. 1H NMR (CDCl3): d (ppm)
8.12 (2H, s, H3 and H5), 7.60 (1H, brs, C(NO2)CNCHCH), 7.29 (1H,
brs, NCHN), 7.05 (1H, brs, CHCHN). MS (EI) m/z 302 [M+] (6), 283
(19), 247 (64), 173 (94), 158 (100). Calc. for C10H5F3N4O4, C,
39.75; H, 1.67; N, 18.54%; found C, 39.83; H, 1.58; N, 18.50%.
2.2.2. 1-(2,6-Dinitro-4-triﬂuoromethyl-phenyl)-1H-benzo[d]imidazole
(TFLA 14)
The general method for synthesis was used with chloralin
(0.273 g, 1 mmol), benzimidazole (0.130 g, 1.1 mmol) and triethyl-
amine (0.15 ml, 1.1 mmol) to obtain the product as yellow crystals
(diethyl ether/hexane, g = 68%). mp 159–160 C. FTIR (KBr): m 3426,
2888, 1551, 1313, 1147 cm1. 1H NMR (CDCl3): d (ppm) 8.60 (2H, s,
H3 and H5), 7.99 (1H, s, NCHN), 7.90 (1H, d, J = 8, CCHCH) 7.40 (1H,
t, J = 7 Hz, CHCHCH), 7.33 (1H, t, J = 8 Hz, CHCHCH), 7.01 (1H, d,
J = 8, CCHCH) MS (EI) m/z 352 [M+] (51), 322 (26), 294 (100), 248
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found C, 47.71; H, 1.90; N, 15.99%.
2.2.3. 4-(2,6-Dinitro-4-
(triﬂuoromethyl)phenylamino)benzenesulfonamide (TFLA 15)
The general method for synthesis was used with chloralin
(0.273 g, 1 mmol), sulfanilamide (0.190 g, 1.1 mmol) and triethyl-
amine (0.15 ml, 1.1 mmol) to obtain the product as yellow crystals
(acetone/petroleum ether, g = 61%). mp 231–233 C. FTIR (KBr): m
3345, 3283, 3256, 1535, 1328, 1155 cm1. 1H NMR (CDCl3): d
(ppm) 8.68 (2H, s, H3 and H5), 7.83 (2H, d, J = 9, CHCS), 7.37 (2H,
d, J = 7 Hz, NHCCH). MS (EI) m/z 406 [M+] (37), 342 (100), 278
(35), 262 (45), 63 (62). Calc. for C13H9F3N4O6S, C, 38.43; H, 2.23;
N, 13.79%; found C, 38.46; H, 1.87; N, 13.83%.
2.3. Determination of water solubility
The water solubility values were obtained from the UV spectra
recorded for each TFLA. Samples were prepared according to the
following general procedure: a suspension of each compound
(5 mg) in water (10 ml) was stirred at room temperature for 1 h,
ﬁltered and the UV spectrum of the ﬁltrate (3 ml) was recorded
and the value of the absorbance at the maximum wavelength
(kmax) was obtained. In order to determine the value of the absorp-
tivity at kmax, a standard solution of known concentration was pre-
pared by dissolving the compound (4 mg) in methanol (10 ml) and
then diluting this solution in water (5, 12.5 and 25 times) followed
by recording the UV spectra for the three dilutions. The value of
absorptivity obtained is the average of the absorptivity values cal-
culated for each dilution by applying the Beer law to the UV data.
With this value of absorptivity, the concentration of each com-
pound in the water sample was calculated.
2.4. In vitro cultivation of B. bovis parasites
Babesia bovis Texas S74-T3Bo (derived from S1-T2Bo, Goff et al.,
1998) and Mo7 (Rodriguez et al., 1983) strains were grown in bo-
vine erythrocytes using a continuous micro-aerophilous stationary
phase system as described by Levy and Ristic (1980). The cultures
were grown in 96-well plate in 10% hematocrit using culture med-
ia, HL-1, pH 7.25, supplemented with 40% bovine serum, 0.5 ml of
100 stock solution of antibiotic/antimitotic (Sigma) and 1 mM
TAPSO solution (Sigma). Cultures were incubated at 37 C in an
atmosphere of 5% CO2, 5% O2 and 90% N2.
2.5. In vitro B. bovis growth inhibition assay
All 14 TFLA (TFLA 1–4 and 6–15) were evaluated for their che-
motherapeutic effect against B. bovis in in vitro culture. All the
compounds were dissolved in DMSO/ethanol 50:50 (v/v) as previ-
ously described (Naughton et al., 2008), to a ﬁnal concentration of
15 mM.
The inhibition assays were performed in a 96-well plate in 10%
hematocrit using 180 ll medium per well containing the respec-
tive TFLA concentration. Initially, concentrations of 10, 50 and
100 lM of all compounds were tested for their inhibitory effect
on B. bovis Mo7 strain, and after choosing the three compounds
with the best inhibitory effect, concentrations of 10, 20, 40, 60,
80 and 100 lM of TFLA 7, TFLA 10 and TFLA 13 were tested for their
inhibitory effect on both Mo7 and T3Bo strains of B. bovis. Four con-
centrations of imidocarb dipropionate (IMIZOL, Schering-Plough
Animal Health Corp.), 1.75, 5, 10 and 20 lM, were tested on addi-
tional cultures. Cultures grown in the absence of drugs and con-
taining only the solvent (DMSO/ethanol) at the highest
concentration used in TFLA (0.7%) were tested as controls. The cul-
ture medium was replaced every day with 180 ll medium per wellcontaining the respective TFLA or imidocarb dipropionate concen-
tration, and the percentage of parasitized erythrocytes (PPE) was
monitored daily by Giemsa-stained erythrocytes smears for 72 h.
The average PPE reached at 72 h in the control wells (no solvents
or drugs added) was approximately 10%. These experiments were
carried out in triplicate for each TFLA concentration. IC50 values
were calculated for each time point of the in vitro culture by
extrapolation from the PPE curve as the concentration in which
there is a 50% reduction of PPE in the wells treated with drugs com-
pared to the control well.
2.6. Hemolytic activity assay
The percentage of hemolytic activity was estimated as previ-
ously described by Naughton et al., 2008. Brieﬂy, the percentage
of hemolytic activity of each TFLA at different concentrations was
estimated as (A  A0/Amax  A0)  100, where A0 is the background
hemolysis obtained by incubation of the B. bovis Mo7 parasites
with culture medium (supernatant) and Amax is the 100% hemolysis
achieved after incubation in water. The 550 nm measures of absor-
bance of each supernatant were taken with a reference ﬁlter at
620 nm. These experiments were carried out in triplicate for each
TFLA concentration.
2.7. Babesia bovis viability assay using 6-carboxyﬂuorescein diacetate
after incubation with TFLA
Babesia bovis Mo7 strain culture was performed in a 96-well
plate in 10% hematocrit using 180 ll medium per well containing
TFLA 7, TFLA 10 and TFLA 13 at 10 lM, imidocarb dipropionate
at 1.75 lM and 5 lM, solvent without drugs (0.7%), or B. bovis
Mo7 parasites growing in regular culture media (no drugs or sol-
vents). All cultures were grown for 72 h as previously described
(Sections 2 and 2.5). The viability assay protocol used was based
on Goff et al., 1988. Brieﬂy, 3.5 ll of B. bovis infected erythrocytes
that were cultured for 72 h were added to 1 ml of citrate saline
solution (0.15 M sodium chloride; 0.01 M sodium citrate) and cen-
trifuged at 400g for 5 min. The resulting pellet was washed twice
with citrate saline solution, suspended into 1 ml of citrate saline
solution containing 2 ll of 6-carboxyﬂuorescein diacetate (CFDA),
and incubated for 20 min at room temperature in the dark. After
centrifugation at 400g for 5 min, the pellet was suspended in
15 ll of citrate saline solution, and 2.5 ll was transferred to a glass
slide containing 0.8 ll of Slow Fade Antifade reagent (Invitrogen).
A cover slip was placed over the top and the slide was examined
under ﬂuorescence microscope at 40 ampliﬁcation. In addition,
the percentage of parasitized erythrocytes (PPE) in B. bovis infected
erythrocytes that were cultured for 72 h was monitored using
standard Giemsa-stained slides with an optical microscope. All via-
bility experiments were carried out in triplicate.
2.8. Bovine renal arterial endothelial cells viability after incubation
with TFLA
Bovine renal arterial endothelial cells (BRAEC) (Cell application
Inc.), kindly provided by Dr. Kerry Sondgeroth, were grown and
maintained according to the manufacturer’s instructions. Brieﬂy,
BRAEC grown in a T-75 ﬂask to 80% conﬂuence were trypsinized
for 1 min, neutralized, centrifuged at 220g for 5 min, re-sus-
pended in 5 ml of bovine endothelial cell growth medium, and
counted with a hemocytometer under a phase contrast micro-
scope. A total of 4000 cells per cm2 were inoculated into a coated
48 well plate using 1 ml medium per well containing the respec-
tive TFLA at 10 lM. Identical cultures were also initiated using imi-
docarb dipropionate at 5 lM. Cultures without TFLA, and
containing only the solvents at the highest concentration used in
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replaced every day for a total of 72 h with 1 ml medium per well
containing the respective drug. BRAEC cultured to 90% conﬂuence
after 72 h were trypsinized for 1 min, neutralized, centrifuged at
220g for 5 min and resuspended in 0.4 ml of bovine endothelial
cell growth medium. Ten microliters of resuspended BRAEC were
transferred to a microcentrifuge tube containing 10 ll of 0.4% Try-
pan blue (Sigma) and the cells were immediately counted with a
hemocytometer under an optical microscope. These experiments
were carried out in triplicate.2.9. Statistical analysis
The difference in the PPE for the in vitro culture with TFLA and
the control (no drug added) were analyzed using independent Stu-
dent’s t test, where p values of <0.05 were considered statistically
signiﬁcant.3. Results and discussion
3.1. The B. bovis a-tubulin amino acid sequence contains conserved
consensus triﬂuralin binding sites
The full a-tubulin amino acid sequences of several parasites
that are sensitive to triﬂuralin analogues were initially compared
with the B. bovis a-tubulin amino acid sequence using the program
ClustalW. The amino acid sequence comparisons showed high
overall similarity among the B. bovis a-tubulin sequence and other
protozoa a-tubulin sequences such as L. major, P. falciparum,
T. gondii, T. brucei gambiense, T. annulata, and also with the
H. sapiens a-tubulin sequence (Fig. 1). Consistent with the phyloge-
netic relationships among these organisms, the highest overall se-
quence identity found for the B. bovis sequence was for T. annulata
(79.0%), followed by T. gondii (74.0%), P. falciparum (73.0%),
T. brucei gambiense (70.0%), L. major (69.0%) and H. sapiens
(65.0%) (Supplementary Fig. 1).
Previous studies demonstrated that certain amino acid residues
of a-tubulin, labeled in gray font in Fig. 1, are critical for the bind-
ing of triﬂuralin (Traub-Cseko et al., 2001; Mitra and Sept, 2006;
Hashim et al., 2012). Furthermore, it was found that certain amino
acid mutations correlate with increased or decreased inhibition of
the target cells growth by triﬂuralin. Importantly, most amino acid
residues which are required for triﬂuralin binding (labeled in gray,
Fig. 1), or that inﬂuence triﬂuralin sensitivity (amino acid in boxes,
Fig. 1), are also conserved in the sequence of the B. bovis a-tubulin.
However, the sequence comparison also shows that the B. bovis a-
tubulin amino acid sequence differs in several residues that may be
important for triﬂuralin binding, including Ser165Thr, Val171Ile,
Leu230Ile, and Gly366Asp. These amino acid polymorphisms
might potentially result in increased dinitroaniline-resistance in
B. boviswhen compared to the highly triﬂuralin sensitive wild type
strain of Leishmania sp., similar to what was previously described
for T. gondii triﬂuralin resistant mutants. Other amino acids that
were found to be present only in B. bovis a-tubulin include: Cys6A-
la, Cys20Val, Met36Val, Lys40Tyr, Cys41Gly, Ile42Ala, Asp47His,
Val235Ile and Ala240Thr (Fig. 1). The N-terminal MREVI a-tubulin
sequence which is involved in triﬂuralin binding (Chan et al., 1993;
Hashim et al., 2012), is conserved among P. falciparum, T. gondii and
B. bovis, but not in L. major, T. brucei, H. sapiens and T. annulata.
Whether the overall changes found in the B. bovis a-tubulin amino
acid sequence result in decreased or increased binding afﬁnity by
triﬂuralin or to novel TFLA compared to other protozoan parasites
remains unknown, and thus we proceeded to test the ability of
TFLA to inhibit the in vitro growth of cultured B. bovis parasites
using the three newly synthetized and the previously tested TFLA1–4 and 6–12 (henceforth referred as TFLA 1–12, although the
TFLA 5 was not available for testing in this study). Although the
deﬁnitive mechanisms of action of TFLA remain unknown, recent
evidence suggests possible scenarios. In P. falciparum it was dem-
onstrated that the dinitroanilines triﬂuralin and oryzalin inhibited
growth of erythrocytic P. falciparum through schizogony, blocked
mitotic division, and caused accumulation of abnormal microtubu-
lar structures (Fennell et al., 2006). It has also been demonstrated
in Toxoplasma that when oryzalin binds to a-tubulin, under the N
loop between protoﬁlaments in the microtubule, it may then inhi-
bit the N loop interaction with the M loop of the adjacent protoﬁl-
ament. This may result in instability of the M–N loop, followed by
microtubule disruption (Snyder et al., 2001; Li et al., 2002;
Morrissette et al., 2004). In addition, Toxoplasma resistance to a
dinitroaniline derivate, oryzalin, is associated with point mutations
in a-tubulin. Interestingly, most mutations leading to oryzalin
resistance cluster in the core of the proteins, affecting the
conformation of the a-tubulin dinitroaniline binding site
(Morrissette et al., 2004).
3.2. Synthesis and chemistry of novel triﬂuralin analogues TFLA 13–15
The synthesis and characterization of TFLA 1 to TFLA 12 were
reported previously (Esteves et al., 2010). Following the same gen-
eral method, the synthesis of the new TFLA, namely TFLA 13–15,
was accomplished by reacting the commercially available chlori-
nated precursor, chloralin, with imidazole, benzimidazole and sul-
fanilamide in the presence of triethylamine using ethanol as
solvent (Fig. 2 and in Supplementary Fig. 2). The resulting new
TFLA 13–15 were obtained in 60–70% yields, and are stable and
easily-handled crystalline solids. The TFLA were fully characterized
by FT-IR, MS, NMR and elemental analysis, and their water solubil-
ity was determined by UV spectrophotometry as described previ-
ously (Esteves et al., 2010). None of the TFLA 13–15 showed
increases in their water solubility in comparison with TFLA 1–12,
displaying low solubility parameters in all cases (<5 ppm).
3.3. Inhibition effect in in vitro B. bovis growth by TFLA 1–15
Because the use of the non-aqueous solvents needed to solubi-
lize TFLA might be inhibitory for B. bovis parasites and/or toxic for
the bovine erythrocytes, we ﬁrst determined the effects of di-
methyl sulfoxide (DMSO) and ethanol solvents on B. bovis in
in vitro culture system, by direct observations of Giemsa stained
cells under an optical microscope using 1000 ampliﬁcation.
Microscopic observations suggest that the addition of a mix of
DMSO/ethanol at the concentration used for solubilizing the four-
teen TFLA tested in this study (0.7% per well) into the B. bovis cul-
ture media does not result in apparent changes in the morphology
of either the parasites or bovine erythrocytes (data not shown).
However, the in vitro B. bovis culture grown in the presence of
DMSO/ethanol showed a decrease in the growth rate of approxi-
mately 9.8% (±6.4) when compared with the in vitro B. bovis growth
rate obtained using regular media (data not shown). These data are
in accordance with previous results suggesting that this solvent
can only slightly inhibit in vitro parasite growth and therefore it
can be considered acceptable for culturing, when added at low con-
centrations into the culture media (Wadhwani et al., 2009).
We then investigated the efﬁcacy of the TFLA on B. bovis para-
sites of the in vitro cultured biologically cloned strain Mo7 by per-
forming the cultures in the presence of 10, 50 and 100 lM of TFLA
1–15. The cultures were examined every 24, 48 and 72 h for
changes in PPE and the possible occurrence of morphology abnor-
malities by optical microscopy. Different levels of inhibition of the
growth of the B. bovis Mo7 strain were observed for all 14 com-
pounds tested when compared to cultures grown in the absence
Fig. 1. CLUSTALW multiple alignment of deduced amino acid sequences of a-tubulin from protozoa parasites Leishmania major (L. major), Trypanosoma brucei gambiense (T.
brucei), Plasmodium falciparum (P. falciparum), Toxoplasma gondii (T. gondii), Babesia bovis (B. bovis), Theileria annulata (T. annulata) and Homo sapiens (H. sapiens). The GenBank
accession numbers are: CAJ02502.1; CBH08955.1; CAA34101.1; AAA30145.1; EDO06790.1; XP_954407.1 and NP_116093.1, respectively. The a-tubulin amino acids involved
in the consensus binding site for dinitroaniline are highlighted in gray (Morrissette et al., 2004; Mitra and Sept, 2006; Hashim et al., 2012). Boxes indicate positions of amino
acids that are not known to be involved in the binding site but might indirectly increase resistance to dinitroanilines, and white font indicates amino acids changes that are
known to increase resistance to dinitroaniline (Traub-Cseko et al., 2001; Morrissette et al., 2004; Mitra and Sept, 2006; Ma et al., 2008; Hashim et al., 2012).
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tion (IC50) values were calculated (lM) and shown in Fig. 3A and in
Supplementary Table 1. TFLA 7, TFLA 10 and the novel TFLA 13
were the compounds that showed the highest B. bovis Mo7 growth
inhibition, with an estimated IC50 (lM) of 8.5 ± 0.3; 9.2 ± 0.2;
8.9 ± 0.7 at 72 h, respectively (Fig. 3B). Furthermore, the IC50 values
for these three TFLA are statistically signiﬁcant with p values <0.05.
The three compounds with the highest inhibitory effect, TFLA 7,
TFLA 10, and TFLA 13, were also tested for their ability to inhibit
the growth of the virulent T3Bo B. bovis strain in cultures. The esti-
mated IC50 values for T3Bo (lM) were 13.6 ± 1.5; 18.7 ± 1.6;10.6 ± 1.9 at 72 h for TFLA 7, TFLA 10 and TFLA 13, respectively
(Fig. 3B), in all cases consistent with the results obtained for the
Mo7 strain. The statistically signiﬁcant differences found among
the IC50’s of the Mo7 and T3Bo parasites might be due to the clonal
nature of the attenuated B. bovis Mo7 strain, in contrast to the
polyclonal and heterogeneous composition of the virulent T3Bo
strain. No apparent morphological changes were detected among
B. bovis parasites exposed to these compounds (data not shown).
In L. infantum, the most effective compounds were TFLA 3, 8 and
10 (with IC50 (lM) of 1.2 ± 0.7; 1.1 ± 0.4, and 0.5 ± 0.1, respectively)
with TFLA 7 having an IC50 (lM) of 2.2 ± 0.5 (Supplementary Ta-
Fig. 2. Representation of the TFLA 1–TFLA 15 structures.
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IC50 (lM) values between B. bovis and L. infantum (Supplementary
Table 2) suggests that the numerous changes in a-tubulin binding
amino acid residues among these molecules do not seem to have
dramatic effects in the levels of sensitivity to triﬂuralin between
these two parasites.
As a positive control we also performed parasite in vitro cultures
in the presence of 5 lM of imidocarb dipropionate, which resulted
in 100% inhibition of both B. bovis strains (data not shown). How-
ever, this drug produced visible morphological changes on both the
T3Bo and Mo7 B. bovis parasites as well as on erythrocytes, and
drug concentrations that are equal or higher than 20 lM resulted
in high levels of erythrocyte lysis as well (data not shown). Addi-
tionally, when imidocarb dipropionate was tested at its IC50 con-
centration (8.7  107 g ml1, or 1.75 lM; Rodriguez and Trees,
1996), caused 99.9% of inhibition of the Mo7 strain, producing sim-ilar visible morphological changes on erythrocytes and parasites as
it was described above for the larger dose. The morphological
changes observed on erythrocytes in imidocarb dipropionate-trea-
ted cultures include the presence of crenated erythrocytes, eryth-
rocyte membrane ghosts, and irregular shaped parasites as
described by Irwin, 2010. The morphology of most imidocarb
dipropionate treated-parasites resemble crisis forms as previously
described by Goff et al. (1998) and Herwaldt et al. (2004) (data not
shown). TFLA 1 to TFLA 12, were also previously tested for their
anti-leishmanial activity (Supplementary Fig. 2) (Esteves et al.,
2010). TFLA 3 and TFLA 6–TFLA 11 were active against the intracel-
lular form of the parasite and in particular the TFLA 3, TFLA 8, and
TFLA 10, showed the highest signiﬁcant reduction of the parasite
load of the cells (Esteves et al., 2010). Although the establishment
of a structure–activity relationship is beyond the objective of this
work, we were able to identify some structural features that might
potentially inﬂuence the anti-B. bovis activity of the drugs. For the
analogues with a linear alkyl substituent in the amino group (TFLA
1 to TFLA 4), the results showed that there is an optimal length of
the alkyl chain, speciﬁcally three carbons (TFLA 2). This trend was
also observed in the anti-leishmanial activity of this series of com-
pounds, but in this case the most active compound has a four car-
bon alkyl chain (TFLA 3) (Esteves et al., 2010). The two isomers,
TFLA 6 and TFLA 7 showed a similar anti-B. bovis activity at 72 h,
with TFLA 7 being the most active of all the compounds tested.
However, the results showed a large decrease in the activity of
the third isomer TFLA 8, which can be related to steric hindrance
due to the proximity of the hydroxyl substituent and the amino
group in the structure of this compound (Esteves et al., 2010).
These proximities also favor the establishment of hydrogen bonds
and might explain the higher water solubility of TFLA 8 when com-
pared with TFLA 6 and TFLA 7. However, increase in water solubil-
ity is not correlated with increased activity, since TFLA 7 is the
most potent inhibitory TFLA derivative tested in this study. An in-
crease in the B. bovis inhibitory activity of these drugs was also ob-
served when comparing results for TFLA 10 and TFLA 12, which is
probably due to the introduction of an oxygen atom in the hetero-
cyclic ring (TFLA 10). This effect was previously observed in the
anti-leishmanial activity assays using TFLA (Esteves et al., 2010).
Together, these observations might help future design of novel
and improved anti-babesicidal TFLA.
3.4. Hemolytic activity of TFLA
We then determined the percentages of hemolysis of bovine
erythrocytes as a surrogate marker of general membrane toxicity
effects (Esteves et al., 2010), upon their exposure to TFLA 7, 10,
and 13, the compounds that have the most potent inhibitory effect
on both B. bovis strains tested (Fig. 4). The hemolytic activity of
these TFLA was tested using a concentration of 10 lM, which is
the approximate average IC50 value found among these three com-
pounds. The data indicates that TFLA 13, which is the most effec-
tive anti-B. bovis compound, causes the less hemolysis (2%)
followed by 3% for TFLA 10 and 4% for TFLA 7, respectively
(Fig. 4). The percentages of hemolysis also augmented with
increasing TFLA concentrations, reaching a maximum of approxi-
mately 11% for TFLA 7 and for TFLA 10 at 100 lM, and approxi-
mately 6% for TFLA 13 at an identical concentration. The
percentage of hemolysis produced by the DMSO/ethanol solvent,
at its highest concentration was of 2.5%. Interestingly, TFLA 7 and
TFLA 10 showed similar curves of hemolysis throughout all the
concentrations tested, from 10 to 100 lM.
Overall, and consistent with data previously reported by Esteves
et al. (2010), these three TFLA display low hemolytic activity on bo-
vine erythrocytes when exposed under a concentration of 20 lM,
suggesting that they have a low level of toxicity for the bovine host
Fig. 3. IC50 (lM) values obtained from TFLA tested in B. bovis culture at 72 h after the addition of the TFLA as indicated in the X axis. (A) IC50 (lM) values from TFLA 1–4 and 6–
15 obtained for the B. bovis Mo7 strain. The TFLA tested with lowest IC50 (TFLA 7, 10, and 13) are represented in white bars; imidocarb dipropionate (IMD) (Rodriguez and
Trees, 1996) is represented in grey bar; (B) IC50 (lM) values for TFLA 7, 10 and 13 obtained for the B. bovisMo7 strain (white bars) and T3Bo strain (black bars). () Represents
p-value <0.05 indicating a statistically signiﬁcant difference between strains. Both assays were carried out in triplicate. Error bars indicate standard error of the means for
each TFLA tested.
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ited much higher hemolytic activities, ranging from 9.5% to 15%
of hemolysis for 5, 10 and 20 lM (Fig. 4). In addition, incubation
of B. bovis cultures with imidocarb dipropionate at the IC50 concen-
tration, (1.75 lM) resulted in a percentage of hemolysis of 6.6%
(Fig. 4). The percentage of viability of these cultured parasites
was 0.1% and B. bovis PPE of 0.1% at 72 h (Fig. 5). These data indi-
cates that imidocarb dipropionate causes stronger hemolytic ef-
fects on bovine erythrocytes than the TFLA, even when used at
the IC50 concentration.
3.5. Parasite and host cell viability after incubation with TFLA
We performed two experiments in order to determine the po-
tential of the TFLA 7, 10 and 13 to affect the parasite and host cellviability after incubation with the drugs for 72 h. To test the effect
of the TFLA on the viability of the parasite, TFLA-treated and non-
treated control B. bovis infected erythrocytes were labeled with
CFDA. Percentages of viable parasites were then determined by
ﬂuorescence microscopy for all treatments. Treatment with TFLA
7, TFLA 10, TFLA 13 and DMSO/ethanol resulted in percentages of
parasite viability of 73, 93, 67 and 97, respectively (Fig. 5). The
incubation of B. bovis infected erythrocytes with TFLA 7 and TFLA
13 resulted in a statistically signiﬁcant decrease on the percentage
of cell viability (p values <0.05), (Fig. 5).
To test the potential of the TFLA 7, 10 and 13 to affect viability
of the bovine cell line BRAEC, we grew these cells in the presence of
the TFLA at 10 lM followed by cell counting after the addition of
Trypan blue. The data shows that neither TFLA 7, TFLA 10 nor the
solvent ethanol/DMSO are able to signiﬁcantly inhibit the growth
Fig. 4. Hemolytic activity calculated after erythrocytes were exposed to TFLA 7 (), TFLA 10 (j) and TFLA 13 (N) at the following concentrations: 10, 20, 40, 60, 80 and
100 lM, and imidocarb dipropionate () used at 1.75, 5, 10 and 20 lM. The hemolytic activity was calculated by measuring the cells supernatant in a spectrophotometer at
550 nm compared with the reference ﬁlter at 620 nm. Absorbance of cell supernatant after bovine erythrocytes incubated with water was considered as 100% hemolysis. All
assays were carried out in triplicate. Error bars indicate the standard error of the means for each TFLA tested.
Fig. 5. Viability of B. bovis infected erythrocytes after incubation with TFLA 7, TFLA 10 and TFLA 13 at 10 lM, imidocarb dipropionate at 1.75 lM and with DMSO/ethanol at
72 h. Y-axis represents percentage of viable parasites [(parasites-labeled with 6-carboxyﬂuorescein diacetate/parasites-stained with Giemsa)  100]. The assays were carried
out in triplicate. Error bars indicate standard error of the means for each TFLA tested. () Represents p-value <0.05 indicating a statistically signiﬁcant difference compared to
the non-treated control.
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percentages of viability that are above 85% (Fig. 6), which is in
accordance with the percentages of viability obtained when no
drugs or additional solvents were applied (non-treated control)
(Fig. 6). However, incubation of BRAEC with TFLA 13 resulted in a
small but statistically signiﬁcant decrease (20%) on the percent-
age of cell viability (p values <0.05), (Fig. 6).Both set of experiments showed that addition of TFLA 7, TFLA 10
and TFLA 13 to B. bovis in vitro cultures resulted in signiﬁcantly de-
creased levels of parasitemia compared to the control non-treated
parasites. However most treated parasites remain viable, suggest-
ing that TFLA might mainly act as cytostatic agents. In addition,
TFLA 7 and TFLA 10 did not shown signiﬁcant toxic effects for bo-
vine cells. Overall, based on the viability and toxicity results, the
Fig. 6. Viability of BRAEC after incubation with TFLA 7, TFLA 10 and TFLA 13 at 10 lM, DMSO/ethanol and non-treated well (without the addition of drugs, represented as NA)
at 72 h using Trypan blue. The assays were carried out in triplicate. Error bars indicate standard error of the means for each TFLA tested. () Represents p-value <0.05
indicating a statistically signiﬁcant difference compared to the non-treated control.
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novel alternatives for the treatment of bovine babesiosis.4. Conclusions
TFLA are able to effectively inhibit the in vitro growth of B. bovis
without signiﬁcantly compromising the host erythrocyte cells. The
TFLA 7, 10 and 13 were found to be the most potent inhibitors of B.
bovis in in vitro cultures, likely acting using a cytostatic mecha-
nism. Neither TFLA 7 nor TFLA 10 exerted signiﬁcant toxic effects
on a bovine cell line, although a small but signiﬁcant effect on
these cells was found for TFLA 13. No dramatic differences in the
IC50’s were found between Leishmania sp. and B. bovis despite sev-
eral changes in the amino acid sequences that are known to be crit-
ical for the binding of a-tubulin to triﬂuralin. Furthermore, this
explanation can be also extended to the triﬂuralin-sensitivity dif-
ferences found among B. bovis, Leishmania sp., T. gondii and P. falci-
parum. However, and because we tested other distinct and novel
TFLA in this study, we are not able to exclude differential sensitiv-
ity due to chemistry differences, and/or differences in drug uptake,
metabolism, export or processing, or other biological features, in
each parasite species. However, experimental evidence suggests
that increased water solubility of the compounds does not neces-
sarily translate into augmented anti-babesicidal activity. Thus,
the differences in sensitivity found can also be reﬂective of the dis-
tinct parasite intracellular lifestyles and their intracellular milieus
among other possible factors.
Further studies, such as docking analysis, would improve our
understanding of the observed differences and guide rational
babesicidal drug designs. Further research aimed at determining
the effect of TFLA in vivomay lead to the development of improved
and more effective methods to control bovine babesiosis using
pharmacological approaches.
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